Voxzogo is the first drug targeting the potential gene of dwarfism, which can increase the height of children aged 5 and above.
In Europe, this injection is the first drug approved for treating dwarfism, and the annual price is 300,000 US dollars. It works by combining with a specific receptor called natriuretic peptide receptor -B (which can reduce the activity of growth regulation genes) to stimulate the growth of children's bones.